The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis
Studies leading to the authorization of drugs to treat incurable solid tumors applying restaging intervals ≥ 8 weeks were associated with lower HRs for PFS. The potential impact of restaging intervals on the results for PFS warrants further investigation.
Authors
- Boštjan Šeruga (ORCID: https://orcid.org/0000-0001-7249-8459)
- Roman Adam (ORCID: https://orcid.org/0000-0003-4522-8335)
- Arnoud J. Templeton (ORCID: https://orcid.org/0000-0002-0847-7087)
- Ariadna Tibau (ORCID: https://orcid.org/0000-0003-0229-6987)
- Alberto Ocaña (ORCID: https://orcid.org/0000-0002-1067-9630)
- Eitan Amir (ORCID: https://orcid.org/0000-0002-3706-525X)
- Jonas A. Zuellig
- Filomena Udry
Institutions
- Universitat Autònoma de Barcelona (ES)
- University of Ljubljana (SI)
- University of Basel (CH)
- University of Toronto (CA)
- Hospital de Sant Pau (ES)
- Princess Margaret Cancer Centre (CA)
- Hospital Clínico San Carlos (ES)
- Institute of Oncology Ljubljana (SI)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- St. Claraspital (CH)
Publication Details
- Journal
- Cancers
- Published
- 2025-04-18
- DOI
- https://doi.org/10.3390/cancers17081359
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00